For October 2020, we have selected the following Covid-19 paper: Hernández-Fernández F. et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain 2020 Jul 9;awaa239. doi: 10.1093/brain/awaa239. Online ahead of print.
For October 2020, we have selected the following Research paper: Livingston G. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.
In this paper, recently published in Stroke, the authors aimed to compare anterior circulation large vessel occlusion stroke severity between patients with and without COVID-19.
In this paper, recently published in Neurocritical Care, the authors conducted a retrospective cohort study of patients with haemorrhagic stroke (both non-traumatic intracerebral haemorrhage and spontaneous non-aneurysmal subarachnoid haemorrhage) who were hospitalised between March 1, 2020, and May 15, 2020, within a major healthcare system in New York, during the coronavirus pandemic.
In this paper, recently published in Arteriosclerosis, Thrombosis, and Vascular Biology, the authors aimed to determine the prevalence of D-dimer elevation in COVID-19 hospitalisation, trajectory of D-dimer levels during hospitalisation, and association with clinical outcomes.
In this longitudinal study, recently published in the European Journal of Neurology, the authors sought to describe the neurological manifestations of patients with COVID‐19 and gain pathophysiological insights especially with respect to the cytokine release syndrome (CRS).
In this paper, recently published in the European Journal of Neurology, the authors reported four cases of COVID‐19‐related encephalopathy. The diagnosis was made in patients with confirmed COVID‐19 who presented with new‐onset cognitive disturbances, central focal neurological signs or seizures.
In this paper, recently published in the Journal of Neurology, Neurosurgery and Psychiatry, the authors report initial findings of an ongoing community based COVID-19 study in a large UK-wide population of people with multiple sclerosis (pwMS) which coincided with the peak of the COVID-19 outbreak in the UK